Literature DB >> 12164723

Body mass index in essential tremor.

Elan D Louis1, Karen Marder, Eva C Jurewicz, Dryden Watner, Gilberto Levy, Helen Mejia-Santana.   

Abstract

BACKGROUND: The pathogenesis of essential tremor (ET) is unknown, but it could be neurodegenerative. Weight loss has been observed in patients with neurodegenerative diseases.
OBJECTIVES: To compare body mass index (BMI) (calculated as weight in kilograms divided by the square of height in meters) in ET cases and controls and to determine whether BMI is correlated with tremor severity and duration.
METHODS: Patients with ET were ascertained from the Neurological Institute of New York, New York, NY. Control subjects were recruited from 2 studies at the same institution. Height and weight were measured and BMI was calculated. Dietary data were collected using a Willett Semi-Quantitative Food-Frequency Questionnaire. Tremor severity was assessed using a clinical scale and the Klove Matthews Motor Steadiness Battery.
RESULTS: The 78 cases and 242 controls were of similar age. Mean (SD) BMI in cases vs controls was 26.5 (5.0) vs 28.2 (4.8) (P =.008). This difference remained significant in an unconditional linear regression analysis that adjusted for age, sex, ethnicity, and years of education (P =.02). Mean daily caloric intake was similar in cases and controls. In cases, BMI was negatively correlated with both measures of tremor severity (r = -0.22; P =.05 and r = -0.24; P =.03) and with tremor duration (r = -0.22; P =.05).
CONCLUSIONS: The BMI was lower in ET cases than in controls, and lower BMI was associated with disease of greater severity and longer duration. Caloric intake did not differ between groups, suggesting that lower BMI is not due to a reduction in calories. Lower BMI may be due to increased energy expenditure in ET.

Entities:  

Mesh:

Year:  2002        PMID: 12164723     DOI: 10.1001/archneur.59.8.1273

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  9 in total

1.  Reduced body mass index in essential tremor: a study of 382 cases and 392 matched controls.

Authors:  E D Louis; M Michalec
Journal:  Eur J Neurol       Date:  2014-11-04       Impact factor: 6.089

2.  Weight change following deep brain stimulation for movement disorders.

Authors:  Roy E Strowd; Michael S Cartwright; Leah V Passmore; Thomas L Ellis; Stephen B Tatter; Mustafa S Siddiqui
Journal:  J Neurol       Date:  2010-03-11       Impact factor: 4.849

3.  Tremor-related quality of life: A comparison of essential tremor vs. Parkinson's disease patients.

Authors:  Elan D Louis; Duarte G Machado
Journal:  Parkinsonism Relat Disord       Date:  2015-04-24       Impact factor: 4.891

4.  Personality in essential tremor: further evidence of non-motor manifestations of the disease.

Authors:  A Chatterjee; E C Jurewicz; L M Applegate; E D Louis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

5.  More Time with Tremor: The Experience of Essential Tremor Versus Parkinson's Disease Patients.

Authors:  Elan D Louis
Journal:  Mov Disord Clin Pract       Date:  2015-07-14

6.  Semi-quantitative data on ethanol consumption in 354 ET cases and 370 controls.

Authors:  Elan D Louis; Monika Michalec
Journal:  J Neurol Sci       Date:  2014-09-30       Impact factor: 3.181

7.  Self-reported physical activity in essential tremor: Relationship with tremor, balance, and cognitive function.

Authors:  Elan D Louis; Kathleen Collins; Brittany Rohl; Sarah Morgan; Daphne Robakis; Edward D Huey; Stephanie Cosentino
Journal:  J Neurol Sci       Date:  2016-05-17       Impact factor: 3.181

8.  Cognitive features of essential tremor: a review of the clinical aspects and possible mechanistic underpinnings.

Authors:  Félix Bermejo-Pareja; Verónica Puertas-Martín
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-09-14

9.  Tandem gait performance in essential tremor patients correlates with cognitive function.

Authors:  Elan D Louis; Ashwini K Rao
Journal:  Cerebellum Ataxias       Date:  2015-01-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.